KYORIN Pharmaceutical Co., Ltd.
Regarding the License Agreement with BIODOL for the Neuropathic Pain Treatment Candidate Compound BDT272
Kyorin Pharmaceutical has entered into a license agreement with BIODOL for the neuropathic pain treatment BDT272, acquiring exclusive rights in Japan, South Korea, and Taiwan. Payments up to 79 million euros are planned.
Key Figures
- Upfront and milestone payments totaling up to 79 million euros
- Acquisition of exclusive development, manufacturing, and sales rights for BDT272 in Japan, South Korea, and Taiwan
- Upfront payment to be recorded as selling, general and administrative expenses (R&D expenses) in the fiscal year ending March 2026
AI要約
Overview of the License Agreement
Kyorin Pharmaceutical has exercised an option and concluded a license agreement with BIODOL Therapeutics for the neuropathic pain treatment candidate compound BDT272. Under this agreement, exclusive rights for development, manufacturing, and sales of the compound in Japan, South Korea, and Taiwan have been obtained, with upfront and milestone payments totaling up to 79 million euros to be paid to BIODOL. BDT272 is expected to exert effective analgesic effects through FLT3 inhibition.
Outlook and Earnings Impact
The upfront payment associated with this agreement is planned to be recorded as selling, general and administrative expenses (R&D expenses) in the fiscal year ending March 2026. Kyorin Pharmaceutical will promptly disclose any information requiring timely disclosure in the future. The company is focusing on the pain therapeutic area and aims to provide new treatment options for pain patients through the development and sales of this compound.
